Loading
Life sciences · Journal article
Cancers · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background/Objectives: Long-term recovery after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is heterogeneous, and early patient-reported outcomes (PROs) may provide clinically relevant information about later survivorship. We examined whether quality of life (QoL), fatigue, and early graft-versus-host disease (GVHD) were associated with PROs at 24 months after allo-HSCT. Methods: Adult allo-HSCT recipients were prospectively followed at six predefined timepoints up to 24 months. The primary early landmark was 6 months (T3), and the primary long-term outcome was 24-month (T6) QoL assessed using the Functional Assessment of Cancer Therapy—Bone Marrow Transplant (FACT-BMT). Fatigue was assessed using the Brief Fatigue Inventory (BFI) and Functional Assessment of Chronic Illness Therapy—Fatigue (FACIT-F). Associations were examined using parsimonious regression models including early GVHD. Results: Twenty-eight participants had PRO data at both T3 and T6. Higher FACT-BMT at T3 was associated with higher FACT-BMT at T6 after adjustment for early GVHD (B = 1.077, 95% CI 1.019–1.135, p < 0.001). Early GVHD remained associated with lower T6 FACT-BMT (B = −6.133, 95% CI −9.373 to −2.893, p < 0.001). Higher BFI and lower FACIT-F at T3 were associated with poorer T6 QoL, while 6-month fatigue was also associated with corresponding 24-month fatigue outcomes. Among patients with GVHD, non-responders had less favorable 24-month fatigue outcomes than responders. Conclusions: PROs at 6 months were strongly associated with 24-month QoL and fatigue. The 6-month assessment may represent a clinically informative survivorship landmark, although larger multicenter studies are needed to confirm these associations.